2. Signaling Pathways
  3. Cytoskeleton
  4. Myosin

Myosin

Myosin

Related Products

PDF 0.33 MB

Myosins are mechanoenzymes that interact with actin filaments and hydrolyse ATP to generate movement and force. This enables myosins to propel the sliding of actin filaments, to produce tension on actin filaments and to walk along these filaments. As a result, myosins can regulate the structure and dynamics of the actin cytoskeleton and affect the localization and transport of cellular components. The different myosins are grouped into classes on the basis of their motor domains. There are 35 known classes of myosin, and humans have 40 myosin genes that fall into 13 classes (I, II, III, V, VI, VII, IX, X, XV, XVI, XVIII, XIX and XXXV).

Myosins are actin-dependent motors that participate in a diverse range of crucial activities, including muscle contraction, intracellular trafficking, cell division, motility, actin cytoskeletal organisation and cell signaling. Myosin malfunction has been implicated in a variety of disorders including deafness, hypertrophic cardiomyopathy, Usher syndrome, Griscelli syndrome and cancer.

Myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. In most cells, MLCK is a transducer for signalling MLC phosphorylation in response to Ca2+ binding to MLCK-associated calmodulin. MLCK-mediated MLC phosphorylation and actomyosin contractility is important in muscle contraction, cell migration, and endo/exocytic processes, and is recognized for its central role in signalling endothelial cell-cell adhesion and barrier function.

Myosin Isoform Specific Products:

Myosin Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-100932A
    ML-9 Free Base
    		Inhibitor
    ML-9 (Free Base) is a selective and potent inhibitor of Akt kinase, inhibits myosin light-chain kinase (MLCK) and stromal interaction molecule 1 (STIM1) activity. ML-9 (Free Base) inhibits inhibits MLCK, PKA and PKC activity with Ki values of 4, 32 and 54 μM, respectively. ML-9 (Free Base) induces autophagy by stimulating autophagosome formation and inhibiting their degradation.
    ML-9 Free Base
  • HY-120997
    E6 Berbamine
    		Inhibitor
    E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia.
    E6 Berbamine
  • HY-152206
    JB062
    		Inhibitor
    JB062 is a nonmuscle myosin inhibitor with IC50 values of 1.6, 5.4, and >100 μM for Skeletal muscle myosin, Cardiac muscle myosin, and Smooth muscle myosin II, respectively. JB062 has cytotoxic to human cancer cells but not normal cells. JB062 can be used in research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
    JB062
  • HY-P10346
    smMLCK peptide
    		Inhibitor
    smMLCK peptide is a specific inhibitor of smooth muscle myosin light chain kinase (smMLCK). The smMLCK peptide mimics the substrate and competitively inhibits the binding of the actual substrate to the enzyme, thereby inhibiting the kinase activity. This inhibition prevents the phosphorylation of the myosin light chain, thus inhibiting muscle contraction.
    smMLCK peptide
  • HY-122200
    Phenamacril
    		Inhibitor 99.39%
    Phenamacril (JS399-19) inhibits activity of myosin I non-competitively with an IC50 of 360 nM through suppression of the ATPase activity, exhibits therefore an antifungal efficacy towards Fusarium species.
    Phenamacril
  • HY-176914
    Myosin-IN-3
    		Inhibitor
    Myosin-IN-3 (Compound 4-1) is a pyrimidine ketone derivative. Myosin-IN-3 exhibits significant anti ferroptotic activity (IC50 = 3.11 μM) while possessing myosin (IC50 = 3.09 μM) inhibitory activity and antioxidant activity (DPPH EC50 = 23.17 μM; MDA EC50 = 55.34 μM). Myosin-IN-3 can be used for research on heart conditions such as hypertrophic cardiomyopathy.
    Myosin-IN-3
  • HY-123634
    (S)-3'-Aminoblebbistatin
    		Inhibitor
    (S)-3'-Aminoblebbistatin is the derivative of Blebbistatin (HY-13813). (S)-3'-Aminoblebbistatin exhibits inhibitory activity against myosin II with an IC50 of 14.1 µM.
    (S)-3'-Aminoblebbistatin
  • HY-13692
    1α-Hydroxyvitamin D5
    		Inhibitor
    1α-Hydroxyvitamin D5 (CARD-024) is a vitamin D analog with extremely low hypercalcemic effects. 1α-Hydroxyvitamin D5 effectively attenuates the pro-fibrotic response of colonic myofibroblasts to TGFβ and high-stiffness substrates by inhibiting the expression of αSMA, the phosphorylation of FAK, and the gene expression of MLCK and ET-1, while activating the anti-inflammatory pathway of IL-1β/COX-2. 1α-Hydroxyvitamin D5 can be used in research related to intestinal fibrosis associated with Crohn's disease.
    1α-Hydroxyvitamin D5
  • HY-152190
    JB002
    		Inhibitor 99.32%
    JB002 is a myosin II inhibitor, with an IC50 of ≤10 μM. JB002 can be used for the research of muscle spasticity, chronic musculoskeletal pain, and hypertrophic cardiomyopathy.
    JB002
  • HY-141810
    MT-134
    		Inhibitor
    MT-134 is a SkMII-specific inhibitor and has excellent exposure in muscles.
    MT-134
  • HY-100984A
    HA-100 hydrochloride
    		Inhibitor
    HA-100 hydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 hydrochloride also used as a ROCK inhibitor.
    HA-100 hydrochloride
  • HY-17680
    Myosin-IN-4
    		Inhibitor
    Myosin-IN-4 (Compound 3), a pyridine-2,4-dione derivative, is a myocardial myosin inhibitor. Myosin-IN-4 has a strong inhibitory activity against cardiac myosin ATPase with an IC50 value of 0.73 μM. Myosin-IN-4 exert a negative inotropic effect by inhibiting myocardial contraction. Myosin-IN-4 can be used for the research on cardiovascular diseases related to cardiac myosin.
    Myosin-IN-4
  • HY-13441G
    (-)-Blebbistatin (GMP)
    		Inhibitor
    (-)-Blebbistatin (GMP) is (-)-Blebbistatin (HY-13441) produced by using GMP guidelines. (-)-Blebbistatin (GMP) is a selective inhibitor of the ATPase activity of non-muscle myosin II.
    (-)-Blebbistatin (GMP)
  • HY-128482
    Diazobenzenesulfonic acid
    		Inhibitor
    Diazobenzenesulfonic acid (4-Sulfobenzenediazonium) is an inhibitor of aliostericeffect for myosin ATPase 13.
    Diazobenzenesulfonic acid
  • HY-12880
    HA-100 dihydrochloride
    		Inhibitor
    HA-100 dihydrochloride is a potent protein kinase inhibitor, with IC50s of 4 μM, 8 μM, 12 μM and 240 μM for cGMP-dependent protein kinase (PKG), cAMP-dependent protein kinase (PKA), protein kinase C (PKC) and MLC-kinase, respectively. HA-100 dihydrochloride also used as a ROCK inhibitor.
    HA-100 dihydrochloride
  • HY-169183
    Myokinasib-II
    		Inhibitor
    Myokinasib-II is a myosin light chain kinase (MLCK) inhibitor, which is a potential target for inflammatory diseases, cancer and other diseases..
    Myokinasib-II
  • HY-170318
    Adhibin
    		Inhibitor
    Adhibin is an allosteric inhibitor for RhoGAP class IX myosin, that inhibits Myo9 ATPase in mammalian and invertebrate with IC50 of 2.5 µM and 2.6 µM. Adhibin binds to the ATPase of myosin, interfers with its motor function, blocks the RhoGTPase related signaling pathway, and affects the cell migration, adhesion and cell division. Adhibin can be used in research about cancer metastasis.
    Adhibin
  • HY-19133
    ME 3407
    		Inhibitor
    ME-3407 (EF-4040) is a H+-K+-ATPase redistribution disruptor and myosin light chain kinase (MLCK) and protein kinase A inhibitor. ME-3407 blocks gastric acid secretion and aminopyrine accumulation by inhibiting microsomal-to-apical membrane redistribution of H+-K+-ATPase and suppressing MLCK-mediated myosin light chain phosphorylation. ME-3407 is promising for research of peptic ulcer.
    ME 3407
  • HY-N15301
    Nocarnickelamide B
    		Inhibitor
    Nocarnickelamide B (Compound 2) is a linear peptide and ROCK1/2 inhibitor. Nocarnickelamide B exhibits dual inhibitory activity against ROCK1 and ROCK2 with IC50s of 14.9 μM and 21.9 μM, respectively. Nocarnickelamide B binds to the ATP-binding site. Nocarnickelamide B inhibits the activation of ROCK-regulated cytoskeletal contraction markers such as the myosin light chain. Nocarnickelamide B is potential for glaucoma reasearch.
    Nocarnickelamide B
  • HY-13813R
    Blebbistatin (Standard)
    		Inhibitor
    Blebbistatin (Standard) is the analytical standard of Blebbistatin. This product is intended for research and analytical applications. Blebbistatin is a selective non-muscle myosin II (NMII) inhibitor, promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Blebbistatin blocks cell migration.
    Blebbistatin (Standard)
Cat. No. Product Name / Synonyms Application Reactivity
Myosin Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.